Regulated contracts reviewed inside your environment.
Paralegent AI runs 18+ specialized agents against your CDAs, clinical trial agreements, material transfer agreements and supply contracts — flagging IP, data-sharing, indemnity, regulatory compliance and publication rights in 2-8 minutes. Deployed in your cloud. Built for life-sciences organizations where contract data cannot leave the controlled environment.
For pharma, biotech and medical-device legal teams reviewing CDAs, clinical trial agreements, MTAs and supply contracts across regulated workflows.
aGENERAL MOTORS COMPANY
MASTER PURCHASE AND SERVICES
AGREEMENT — GENERAL TERMS AND CONDITIONS
Master Purchase of Materials and Provision of Services
9. Limitation of Liability
Vendor's total aggregate liability arising out of or related to this Agreement shall not exceed the lesser of (i) USD 50,000 or (ii) the fees paid by Customer to Vendor in the prior three (3) months. The foregoing limitation shall apply notwithstanding any failure of essential purpose of any limited remedy.
12. Term and Termination
This Agreement shall commence on the Effective Date and shall continue for an initial term of one (1) year. Thereafter, this Agreement shall automatically renew for successive one-year terms unless either Party provides thirty (30) days' written notice of non-renewal prior to the then-current expiration date.
14. Governing Law and Jurisdiction
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to its conflict of laws principles. The Parties hereby submit to the exclusive jurisdiction of the state and federal courts located in New York County, New York.
15. Indemnification
Each Party shall indemnify, defend, and hold harmless the other Party from and against any and all third-party claims, losses, damages, liabilities, costs, and expenses arising out of or in connection with breach of representations, warranties, or material obligations under this Agreement.
Regulated contracts demand a different architecture.
Three structural pressures unique to pharma and life-sciences legal teams — and why SaaS contract AI is rarely a viable answer.
Data residency — patient and trial data implications
Clinical trial agreements, master clinical research agreements and informed-consent-linked documents touch jurisdictions and data categories where cross-border processing is heavily regulated. Sending drafts to a vendor cloud is rarely acceptable to the compliance, privacy or QA function.
IP & publication rights — load-bearing clauses
Research collaborations, MTAs and CTAs negotiate IP ownership of background, foreground and derivative results, publication and embargo rights, and license carve-outs for academic vs commercial use. These clauses move strategic value — they cannot be left to template defaults.
Regulatory reps — FDA, EMA, GCP, GDPR, HIPAA
Compliance with GCP, FDA 21 CFR Part 11, EMA guidelines, HIPAA, GDPR Article 9, sub-investigator obligations, audit rights and inspection-readiness reps are non-optional. The legal team needs to know every contract carries the right reps without re-reading every contract.
Compliance by architecture. Not by promise.
Built for regulated contracts.
IP, data and publication clauses, analyzed consistently.
18+ agents analyze IP ownership (background, foreground, derivative), publication rights and embargo windows, MTA permitted-use language, indemnity scope, sub-investigator obligations, audit and inspection rights — every CTA, every MTA, every research collaboration. Preferred positions codified once in the playbook and applied uniformly across study sites and counterparties.
Confidentiality, term and supply continuity, flagged against your standard.
CDAs are negotiated at high volume across business development, R&D and commercial functions. A confidentiality specialist analyzes scope, term, return-and-destroy obligations and residual-knowledge carve-outs. Supply and manufacturing contracts (API, drug product, CMO) layer in quality agreements, GMP reps, capacity commitments and minimum-purchase obligations.
GCP, FDA, GDPR and HIPAA reps consistently present.
A regulatory-compliance specialist checks every contract for the right reps and warranties tied to GCP, FDA 21 CFR Part 11, EMA guidelines, HIPAA, GDPR Article 9 special-category data, and country-specific clinical research law. Missing or watered-down reps surface as RED with the rationale and a suggested revision in your preferred language.
What changes for pharma legal.
Five outcomes that show up at the GC, Chief Compliance Officer and Head of Clinical level inside the first deployment year.
- Contract data stays in your environment. 18+ agents run inside your cloud tenant. Patient-linked, trial-linked and counterparty-proprietary content never leaves the controlled environment.
- CDA backlog cleared. High-volume CDAs across BD, R&D and commercial cleared same-day. The function stops being a bottleneck on partnering and diligence conversations.
- Multi-site CTA consistency. Every study site reviewed against the same playbook. IP, publication, indemnity and regulatory reps treated identically — no site-by-site variance from reviewer drift.
- Regulatory reps verified. GCP, FDA, EMA, HIPAA and GDPR reps checked on every applicable contract. Missing or watered-down reps surface before signature, not at audit.
- Outside counsel reserved for strategy. External firms used for partnering, licensing, M&A and disputes — not for the line-by-line review on every CDA and routine CTA.
In short. 18+ agents in your cloud, applied to every regulated contract, on one consistent playbook.
Paralegent vs status quo in life sciences.
How the in-cloud accelerator compares to the typical workflow inside a pharma or biotech legal department.
| Dimension | Paralegent AI | Manual + Outside Counsel |
|---|---|---|
| Data residency | Your cloud — never leaves | Outside-counsel inbox |
| Review time per CTA | 30 minutes | 20-40 hours |
| CDA throughput | Same-day across business units | Days, reviewer-bound |
| Multi-site CTA consistency | Same playbook every site | Site-by-site variance |
| IP & publication clauses | Specialist analyzes coverage | High variance |
| Regulatory reps coverage | Verified per contract | Manual checklist if any |
| Audit trail per contract | Every redline + rationale logged | Reviewer notes if any |
| Outside-counsel spend | Reserved for strategic deals | Used for first-pass review |
Related capabilities.
NDA Review
High-volume confidentiality agreements reviewed in minutes.
Enterprise
Data sovereignty, scale and one-time deployment for $200M+ companies.
Contract Review
The end-to-end review experience — MSA in, redlines out.
Cloud Deployment
Your cloud. Your data. Azure, AWS, Google Cloud.
Ready to review regulated contracts in your cloud?
Request a demo — we will walk through CTA, CDA and MTA review live, against a contract you bring, inside an environment that meets your data-residency requirements.
Frequently asked questions
What pharma and life-sciences contract types does Paralegent AI cover?
Clinical trial agreements (CTAs), master clinical research agreements, CDAs / NDAs, material transfer agreements (MTAs), research collaboration agreements, supply and CMO contracts, quality agreements, distribution agreements, licensing agreements and consulting agreements. The playbook configures specialist behavior per contract type, so 18+ agents apply the right standard to the right document.
How does Paralegent AI meet our data-residency requirements?
Paralegent AI deploys inside your Azure, AWS or Google Cloud tenant. 18+ agents run on your infrastructure using your LLM accounts in your chosen region. Contract drafts, counterparty data and trial-linked content never leave the controlled environment. Zero data egress to Paralegent servers.
How does it handle multi-site CTAs?
Every study site is reviewed against the same playbook — IP ownership, publication rights, sub-investigator obligations, audit rights, indemnity, regulatory reps, payment terms. Site-by-site variance from reviewer drift disappears. When the playbook updates (new ICH guidance, country law change), every subsequent CTA picks up the new standard automatically.
Can it analyze IP and publication clauses on MTAs and research agreements?
Yes. An IP specialist analyzes background-IP ownership, foreground-IP allocation, derivative-result ownership, permitted-use scope and license carve-outs (academic vs commercial). A publication specialist analyzes embargo windows, review rights, redaction rights and named-author obligations. Each is classified GREEN, ORANGE or RED against the playbook.
How does it handle regulatory representations and warranties?
A regulatory-compliance specialist verifies that every contract carries the required reps — GCP, FDA 21 CFR Part 11, EMA, HIPAA, GDPR Article 9 special-category data and country-specific clinical research law. Missing or watered-down reps surface as RED with the rationale and a suggested revision.
Does Paralegent AI carry FDA or EMA certifications?
Paralegent AI does not certify the regulatory posture of your contracts — your legal and regulatory teams remain accountable for that. What it does: ensures the right reps are consistently present and flagged when missing or weakened, surfaces deviations from your standard, and logs the rationale for every redline so your audit trail is defensible. The system itself runs entirely within your cloud provider's compliance-certified envelope.
Can we maintain different playbooks for different study phases or product lines?
Yes. Multiple playbooks per deployment — Phase I, Phase II/III, registrational, post-marketing, BD, supply, commercial. Each maintains its own 80-150-term playbook. 18+ agents apply the correct playbook automatically based on contract type and counterparty.
How does this handle CDAs across BD, R&D and commercial?
A confidentiality specialist analyzes scope, term, permitted-use, return-and-destroy obligations and residual-knowledge carve-outs. CDAs are high volume across business development, R&D collaborations and commercial discussions — the function clears them same-day rather than spending reviewer hours on routine paper.
What does implementation look like for a pharma legal team?
8-10 week implementation with a dedicated pod of 3-4 engineers. Weeks 1-2: playbook design for primary contract types (typically CTA, CDA, MTA). Weeks 3-4: cloud deployment inside your tenant. Weeks 5-6: Word Add-in plus CLM integration. Weeks 7-8: testing against real contracts. Weeks 9-10: training and go-live across the legal function.
Does this replace our outside counsel?
No. It compresses first-pass review so outside counsel is reserved for partnering, licensing, M&A, regulatory and disputes — work where they add real strategic value. Most pharma legal departments redirect outside-counsel spend rather than cut it.
How does the system handle GDPR Article 9 and HIPAA terms?
A privacy specialist analyzes Article 9 lawful-basis language, special-category-data processing terms, HIPAA business-associate language where applicable, data-residency commitments, sub-processor flow-down and breach-notification windows. Each is classified against the playbook with the rationale logged for audit.